# Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/APLS
## Company Profile
- Ticker: APLS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology, Rare Disease
## Stock Data
- Close: 41.03 USD
- Market cap: 5252712995.31 USD
- Last updated: 2026-05-13
## Business Overview
### Complement C3 Biology
Apellis Pharmaceuticals develops medicines that inhibit complement protein C3, a central control point in the complement cascade. Its portfolio applies the same core biology to retinal, hematologic and renal diseases.
### SYFOVRE
SYFOVRE is an intravitreal pegcetacoplan therapy and the first approved treatment for geographic atrophy secondary to age-related macular degeneration. Apellis retains worldwide ophthalmology rights and is developing a prefilled-syringe presentation.
### EMPAVELI
EMPAVELI, or systemic pegcetacoplan, is approved in the United States for paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. Sobi commercializes systemic pegcetacoplan outside the United States.
### Rare-Kidney Expansion
Pivotal studies are evaluating EMPAVELI in focal segmental glomerulosclerosis and delayed graft function. These programs extend systemic C3 inhibition into additional kidney diseases with substantial complement involvement.
### Next-Generation Pipeline
APL-3007 is being combined with SYFOVRE in Phase 2 to achieve broader complement blockade in the retina and choroid. APL-90992 is a preclinical base-editing program intended to create a one-time treatment targeting the neonatal Fc receptor.
## Why The Stock Is Moving

Current closing-price context is not available for APLS.

## Future Catalysts

- Regulatory submission for the SYFOVRE prefilled syringe planned in the first half of 2026.
- IND submission for APL-90992 planned in the second half of 2026.
- Topline Phase 2 data for SYFOVRE plus APL-3007 expected in 2027.

## Recent News
- 2026-03-31 10:59 EST — [Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology](https://biopharmsignal.com/news/APLS/biogen-to-acquire-apellis-enhancing-the-company-s-growth-portfolio-in-immunology-and-rare-disease-bolstering-growth-outlook-and-accelerating-expansion-into-nephrology) — Source: Apellis Pharmaceuticals
- 2026-03-02 12:00 EST — [Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors](https://biopharmsignal.com/news/APLS/apellis-announces-mikael-dolsten-m-d-ph-d-to-join-board-of-directors) — Source: Apellis Pharmaceuticals
- 2026-02-24 12:05 EST — [Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/APLS/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: Apellis Pharmaceuticals
- 2026-02-23 12:00 EST — [Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference](https://biopharmsignal.com/news/APLS/apellis-pharmaceuticals-to-present-at-the-td-cowen-46th-annual-health-care-conference) — Source: Apellis Pharmaceuticals
- 2026-02-19 12:00 EST — [Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting](https://biopharmsignal.com/news/APLS/apellis-announces-eight-oral-presentations-at-the-49th-macula-society-annual-meeting) — Source: Apellis Pharmaceuticals